ODM-201, also known as Darolutamide, is a new-generation, potent and selective androgen receptor (AR) inhibitor which is potential useful for treatment of castration-resistant prostate cancer (CRPC). ODM-201 is a full and high-affinity AR antagonist that, similar to second-generation antiandrogens enzalutamide and ARN-509, inhibits testosterone-induced nuclear translocation of AR. Importantly, ODM-201 also blocks the activity of the tested mutant ARs arising in response to antiandrogen therapies, including the F876L mutation that confers resistance to enzalutamide and ARN-509. In addition, ODM-201 reduces the growth of AR-overexpressing VCaP prostate cancer cells both in vitro and in a castration-resistant VCaP xenograft model. ODM-201 overcomes resistance to AR-targeted therapies by antagonizing both overexpressed and mutated ARs. ODM-201 is currently in a phase 3 trial in CRPC.
Pan, Tingting; Xia, Chunguang; Yang, Yulei; Zhang, Aiming. Process and intermediates for preparation of androgen receptor antagonist. Assignee Lianyungang Runzhong Pharmaceutical Co., Ltd., Peop. Rep. China; Shanghai Institute of Pharmaceutical Industry. CN 108218908. (2018).
Laitinen, Ilpo; Karjalainen, Oskari. Process for the preparation of androgen receptor antagonists and intermediates thereof. Assignee Orion Corporation, Finland. WO 2016162604. (2016).
Tormakangas, Olli; Wohlfahrt, Gerd; Salo, Harri; Ramasubramanian, Rathna Durga; Patra, Pranab Kumar; Martin, Arputharaj Ebenezer; Heikkinen, Terhi; Vesalainen, Anniina; Moilanen, Anu; Karjalainen, Arja. Preparation of heteroaryl carboxamides as androgen receptor modulators. Assignee Orion Corporation, Finland. WO 2012143599. (2012).
